PL2332968T3 - Stabilizowane alfa-helikalne peptydy i ich zastosowania - Google Patents

Stabilizowane alfa-helikalne peptydy i ich zastosowania

Info

Publication number
PL2332968T3
PL2332968T3 PL10195495T PL10195495T PL2332968T3 PL 2332968 T3 PL2332968 T3 PL 2332968T3 PL 10195495 T PL10195495 T PL 10195495T PL 10195495 T PL10195495 T PL 10195495T PL 2332968 T3 PL2332968 T3 PL 2332968T3
Authority
PL
Poland
Prior art keywords
activating
alpha
cell death
inhibiting cell
helical peptides
Prior art date
Application number
PL10195495T
Other languages
English (en)
Inventor
Loren D. Walenski
Gregory Verdine
Stanley J. Korsmeyer
Original Assignee
Dana-Farber Cancer Institute, Inc.
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc., President And Fellows Of Harvard College filed Critical Dana-Farber Cancer Institute, Inc.
Publication of PL2332968T3 publication Critical patent/PL2332968T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
PL10195495T 2003-11-05 2004-11-05 Stabilizowane alfa-helikalne peptydy i ich zastosowania PL2332968T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51784803P 2003-11-05 2003-11-05
US59154804P 2004-07-27 2004-07-27

Publications (1)

Publication Number Publication Date
PL2332968T3 true PL2332968T3 (pl) 2017-08-31

Family

ID=34576814

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10195495T PL2332968T3 (pl) 2003-11-05 2004-11-05 Stabilizowane alfa-helikalne peptydy i ich zastosowania
PL04811198T PL1680443T3 (pl) 2003-11-05 2004-11-05 Stabilizowane alfa-helikalne peptydy i ich zastosowanie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04811198T PL1680443T3 (pl) 2003-11-05 2004-11-05 Stabilizowane alfa-helikalne peptydy i ich zastosowanie

Country Status (17)

Country Link
US (6) US7723469B2 (pl)
EP (4) EP2332968B1 (pl)
JP (5) JP5122142B2 (pl)
CN (3) CN103467588B (pl)
AU (1) AU2004287884C1 (pl)
BR (1) BRPI0416258A (pl)
CA (2) CA2830063C (pl)
CY (1) CY1114944T1 (pl)
DK (2) DK1680443T5 (pl)
ES (2) ES2437567T3 (pl)
HK (1) HK1089191A1 (pl)
IL (3) IL175152A (pl)
PL (2) PL2332968T3 (pl)
PT (2) PT1680443E (pl)
SI (1) SI1680443T1 (pl)
WO (1) WO2005044839A2 (pl)
ZA (1) ZA200603565B (pl)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20040171809A1 (en) 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
EP2332968B1 (en) * 2003-11-05 2016-05-04 Dana-Farber Cancer Institute, Inc. Alpha-helical peptides suitable for activating or inhibiting cell death
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
FR2881430B1 (fr) * 2005-02-01 2010-10-22 Servier Lab Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
EP2517720A1 (en) 2006-10-05 2012-10-31 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
EP2997973A1 (en) 2006-11-15 2016-03-23 Dana-Farber Cancer Institute, Inc. Stabalized maml peptides and uses thereof
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2686827C (en) * 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
AU2013231104B2 (en) * 2007-01-31 2016-05-12 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2016210709B2 (en) * 2007-01-31 2018-04-19 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2118123B1 (en) * 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP3301108A1 (en) 2007-02-23 2018-04-04 Aileron Therapeutics, Inc. Triazole macrocycle systems
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
ES2637687T3 (es) 2007-05-02 2017-10-16 Dana-Farber Cancer Institute, Inc. Péptido BAD de dominio BH3 para usar en el tratamiento o retardo de la aparición de la diabetes
CA2700925C (en) * 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
US8871899B2 (en) * 2007-12-31 2014-10-28 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
WO2009108261A2 (en) * 2008-01-23 2009-09-03 Dana Farber Cancer Institute Compositions and methods for the treatment of viral infections
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
AU2014201269B2 (en) * 2008-02-08 2016-09-15 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
KR20100126361A (ko) * 2008-02-08 2010-12-01 에일러론 테라퓨틱스 인코포레이티드 치료용 펩티드유사 거대고리
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
US20090326192A1 (en) * 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
AU2009244400B2 (en) 2008-05-06 2012-12-20 New York Blood Center Antiviral cell penetrating peptides
US20110250685A1 (en) * 2008-06-03 2011-10-13 Nash Huw M Compositions and methods for enhancing cellular transport of biomolecules
WO2010011313A2 (en) * 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
US8586707B2 (en) * 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
JP2012503024A (ja) * 2008-09-22 2012-02-02 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
CA2737921C (en) 2008-09-22 2019-01-15 Aileron Therapeutics, Inc. Methods for preparing purified alpha-helical peptidomimetic macrocycle compositions with low metal ppm levels
AU2009294872A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
ES2666458T3 (es) * 2008-09-22 2018-05-04 Aileron Therapeutics, Inc. Macrociclos peptidomiméticos
WO2010034026A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010042225A2 (en) 2008-10-10 2010-04-15 Dana Farber Cancer Institute Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
US9458202B2 (en) * 2008-11-24 2016-10-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
CA2746256C (en) 2008-12-09 2020-03-24 Loren D. Walensky Methods and compositions for specific modulation of mcl-1
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
BRPI1006139A2 (pt) 2009-01-14 2017-05-30 Aileron Therapeutics Inc macrociclos peptidomiméticos
US8312468B2 (en) * 2009-06-09 2012-11-13 Open Kernel Labs Methods and apparatus for fast context switching in a virtualized system
CA2761568C (en) 2009-06-18 2020-10-13 Dana-Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
US9296805B2 (en) 2009-06-18 2016-03-29 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
US9163330B2 (en) 2009-07-13 2015-10-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
EP2480565A4 (en) 2009-09-22 2014-01-01 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
CA2777700A1 (en) * 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
CA2802485C (en) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
WO2011159882A2 (en) * 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Novel stabilized insulin agonists
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012065181A2 (en) 2010-11-12 2012-05-18 Dana Farber Cancer Institute, Inc. Cancer therapies and diagnostics
US9243040B2 (en) 2010-11-30 2016-01-26 The Board Of Trustees Of The University Of Illinois Stable helical ionic polypeptides
US9029332B2 (en) 2010-12-15 2015-05-12 The Research Foundation For The State University Of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
JP6150726B2 (ja) * 2011-03-09 2017-06-21 Jitsubo株式会社 新規な非ペプチド性架橋構造を含む架橋ペプチド、ならびに該架橋ペプチドの合成方法および該方法に用いる新規な有機化合物
EP2688904B1 (en) 2011-03-21 2017-12-27 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
EP2697254B1 (en) 2011-04-15 2018-06-06 Dana-Farber Cancer Institute, Inc. Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
AU2012362121B2 (en) 2011-12-29 2017-08-03 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
WO2013116829A1 (en) 2012-02-03 2013-08-08 The Trustees Of Princeton University Novel engineered potent cytotoxic stapled bh3 peptides
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US10393733B2 (en) 2012-09-19 2019-08-27 Dana-Farber Cancer Institute, Inc. Dynamic BH3 profiling
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
PT2920197T (pt) * 2012-09-26 2021-06-11 Harvard College Péptidos agrafados com bloqueio de prolina e suas utilizações
WO2014055564A1 (en) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
SG11201502584XA (en) * 2012-10-01 2015-05-28 Agency Science Tech & Res Peptides and methods for treating cancer
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
SG11201503052RA (en) * 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
WO2014081953A1 (en) 2012-11-21 2014-05-30 Richard David J Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
US9493510B2 (en) * 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
EP2964245A4 (en) * 2013-01-19 2016-09-21 Univ New York PEPTIDES AND PEPTIDOMIMETIC HYDROGEN-LINKED SUBSTITUTE FOR REACTIVATION OF P53
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
SG10201913593WA (en) * 2013-03-13 2020-02-27 Harvard College Stapled and stitched polypeptides and uses thereof
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
US10308926B2 (en) 2013-03-15 2019-06-04 Dana-Farber Cancer Institute, Inc. Stablized EZH2 peptides
EP2970417B1 (en) * 2013-03-15 2019-06-19 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
ES2901704T3 (es) 2013-03-15 2022-03-23 Protagonist Therapeutics Inc Análogos de hepcidina y usos de los mismos
CA2906740A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN104211751B (zh) * 2013-05-29 2018-05-22 北京大学深圳研究生院 一种将多肽稳定为alpha螺旋二级结构的方法
CA2915354A1 (en) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP2835135A3 (en) 2013-06-19 2015-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Means and methods for treating pseudomonas infection
US9644002B2 (en) 2013-07-25 2017-05-09 Yale University Allosteric modulators of EGFR and constitutively active mutants
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
US10739333B2 (en) 2013-09-19 2020-08-11 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
JP2017503749A (ja) * 2013-10-01 2017-02-02 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化されたポリペプチドおよびその使用
US10464970B2 (en) 2013-10-23 2019-11-05 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds that bind to human immunodeficiency virus rev response element
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
CN104926924B (zh) * 2014-03-17 2019-03-19 北京大学深圳研究生院 一种利用手性锍盐侧链稳定多肽α-螺旋二级结构的方法
EP3119477B1 (en) 2014-03-20 2020-01-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
WO2015153560A1 (en) 2014-03-31 2015-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
EP3131922B1 (en) 2014-04-17 2020-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides and uses thereof for reducing cd95-mediated cell motility
SG10201810321PA (en) 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
WO2015179635A2 (en) * 2014-05-21 2015-11-26 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
CN106661582A (zh) * 2014-05-30 2017-05-10 阿尔伯特爱因斯坦医学院公司 Bax靶向二聚化以调节bax活性
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
EP3200812B8 (en) 2014-10-01 2021-04-28 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
CN105566456B (zh) * 2014-10-09 2019-03-19 北京大学深圳研究生院 末端侧链-尾链连接手性二酸修饰多肽化合物及合成方法
WO2016085280A1 (ko) * 2014-11-28 2016-06-02 서울대학교산학협력단 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
CN107406881B (zh) 2015-01-12 2021-05-25 尤特罗皮克斯制药股份有限公司 用于指导癌症治疗的内容相关的诊断测试
AU2016232833A1 (en) 2015-03-18 2017-10-12 Dana-Farber Cancer Institute, Inc. Selective Mcl-1 binding peptides
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016164768A1 (en) * 2015-04-08 2016-10-13 University Of Georgia Research Foundation, Inc. Disruption of the wave3 protein complex for suppression of invasion and metastasis
WO2016167291A1 (ja) 2015-04-13 2016-10-20 国立研究開発法人産業技術総合研究所 環状化サイトカイン及びその製法
CA2982928A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
WO2016176299A1 (en) 2015-04-27 2016-11-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using dynamic bh3 profiling
KR102608921B1 (ko) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. 생체 이용률이 증가된 알보시딥 프로드러그
WO2016209978A2 (en) 2015-06-22 2016-12-29 University Of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
MX2017016251A (es) * 2015-07-02 2018-04-20 Dana Farber Cancer Inst Inc Peptidos anti-microbianos estabilizados.
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN108289861B (zh) 2015-08-03 2021-11-02 大日本住友制药肿瘤公司 用于治疗癌症的组合疗法
US20190002506A1 (en) * 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
AU2016316842C1 (en) 2015-08-28 2021-04-22 Dana-Farber Cancer Institute, Inc. Peptides binding to BFL-1
CN108368161A (zh) * 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017147283A1 (en) * 2016-02-23 2017-08-31 Dana-Farber Cancer Institute, Inc. Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting
CN109069578A (zh) * 2016-02-29 2018-12-21 达纳-法伯癌症研究所股份有限公司 用于治疗感染的钉合的细胞内靶向抗微生物肽
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
US10618939B2 (en) * 2016-06-29 2020-04-14 The Hong Kong Polytechnic University Hydrocarbon-stapled polypeptides for enhancement of endosome-lysosomal degradation
CN107540737B (zh) * 2016-06-29 2023-03-28 香港理工大学 用于促进内体及溶酶体生物降解的碳氢订书肽
US11567082B2 (en) 2016-07-01 2023-01-31 Dana-Farber Cancer Institute, Inc. Compositions, assays, and methods for direct modulation of fatty acid metabolism
WO2018017485A1 (en) 2016-07-17 2018-01-25 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
ES2935622T3 (es) 2016-08-26 2023-03-08 Dana Farber Cancer Inst Inc Polipéptidos y miméticos de bcl-w para el tratamiento o la prevención de la neuropatía periférica y la pérdida auditiva inducidas por la quimioterapia
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018119000A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
WO2018140613A1 (en) 2017-01-25 2018-08-02 The Board Of Trustees Of The University Of Illinois Conformation switchable antimicrobial peptides and methods of using the same
US11325955B2 (en) 2017-07-19 2022-05-10 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
US11236128B2 (en) 2017-07-31 2022-02-01 Agency For Science, Technology And Research Method of preparing stapled peptides
KR20200064075A (ko) 2017-09-07 2020-06-05 포그 파마슈티컬스 인코포레이티드 베타-카테닌 기능을 조절하는 제제 및 이의 방법
WO2019051494A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND USES THEREOF
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
WO2019090015A1 (en) 2017-11-03 2019-05-09 Yale University Peptidic materials that traffic efficiently to the cell cytosol and nucleus
US11591365B2 (en) 2017-11-09 2023-02-28 Wntrx Pharmaceuticals Inc. BCL9 peptides and variants thereof
WO2019118893A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
WO2019118719A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides
WO2019136209A1 (en) * 2018-01-05 2019-07-11 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
CA3089279A1 (en) 2018-02-07 2019-08-15 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2019178313A1 (en) 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Stabilized peptides for biomarker detection
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11286299B2 (en) 2018-09-17 2022-03-29 Massachusetts Institute Of Technology Peptides selective for Bcl-2 family proteins
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
AU2020258482A1 (en) 2019-04-18 2021-10-14 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like E1-activating enzymes by structurally-stabilized peptides
CN110452289A (zh) * 2019-07-10 2019-11-15 江苏申琅生物科技有限公司 一类新型mdm2环肽抑制剂的设计及其制备方法
MX2022000397A (es) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
US20230116760A1 (en) 2019-12-16 2023-04-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
AU2020408070A1 (en) 2019-12-20 2022-06-09 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
US11845808B2 (en) 2020-01-15 2023-12-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021230544A1 (en) 2020-03-04 2022-09-01 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized SARS-CoV-2 peptides and uses thereof
WO2021216845A1 (en) 2020-04-22 2021-10-28 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
CA3179873A1 (en) 2020-04-27 2021-11-04 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
CN116801908A (zh) 2020-10-14 2023-09-22 丹娜法伯癌症研究院 用于降解病毒和宿主蛋白的嵌合缀合物和使用方法
WO2022109328A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
MX2024002824A (es) 2021-09-08 2024-06-28 Dana Farber Cancer Inst Inc Conjugados antivirales de peptido de coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2)-colesterol estructuralmente engrapados y usos de los mismos.
WO2023159113A1 (en) 2022-02-16 2023-08-24 Greene Warner C Peptide fusion inhibitors exhibiting pan-coronavirus inhibitory activity
WO2023215784A1 (en) 2022-05-04 2023-11-09 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US517848A (en) 1894-04-10 Bolt-cutter
US591548A (en) 1897-10-12 Pocket-case
US4730006A (en) 1986-01-27 1988-03-08 Merrell Dow Pharmaceuticals Inc. Derivatives of 2,6-diamino-3-haloheptanedioic acid
US5120859A (en) 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
US5712418A (en) 1989-10-23 1998-01-27 Research Corporation Technologies, Inc. Synthesis and use of amino acid fluorides as peptide coupling reagents
US5245009A (en) * 1990-03-23 1993-09-14 The Salk Institute For Biological Studies CRF antagonists
DE69118826T2 (de) * 1990-11-27 1996-11-14 Fuji Photo Film Co Ltd Propenamidderivate, deren Polymere, Copolymere und deren Verwendung
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
AU691645B2 (en) 1992-04-03 1998-05-21 California Institute Of Technology High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
IL109943A (en) * 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US6407059B1 (en) * 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
US7553929B2 (en) * 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5770377A (en) 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
EP0729972A1 (de) * 1995-02-28 1996-09-04 F. Hoffmann-La Roche Ag Tetrahydronaphthalin-Peptidderivate
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5672584A (en) * 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
DK0832096T3 (da) 1995-05-04 2001-10-01 Scripps Research Inst Syntese af proteiner ved nativ kemisk ligering
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5663316A (en) 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
CA2259149A1 (en) 1996-07-05 1998-01-15 Novartis Ag Inhibitors of the interaction between p53 and mdm2
US5911495A (en) * 1996-09-03 1999-06-15 Midiri, Jr.; Paul Plant lamp fixture
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
DE69735241T2 (de) 1996-11-21 2006-11-02 Promega Corp., Madison Alkyl peptidamide für topische verwendung
EA199900752A1 (ru) * 1997-02-20 2000-06-26 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Противопатогенные синтетические пептиды и композиции, их включающие
US6849428B1 (en) 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
CA2304124A1 (en) 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Bci-2-like protein bim and methods of use thereof
US6165732A (en) * 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6875594B2 (en) 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
CA2316834C (en) 1998-01-07 2006-01-03 Shearwater Polymers, Inc. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
HUP0101629A2 (en) * 1998-04-15 2003-03-28 Aventis Pharma Inc Process for the preparation of resin-bound cyclic peptides
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
WO2000052210A2 (en) 1999-03-01 2000-09-08 Variagenics, Inc. Methods for targeting rna molecules
KR100558131B1 (ko) * 1999-03-29 2006-03-10 더 프록터 앤드 갬블 캄파니 멜라노코르틴 수용체 리간드를 함유하는 약제학적 조성물및 멜라노코르틴 수용체 리간드를 함유하는 약제의제조방법
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) * 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6495674B1 (en) * 2000-02-25 2002-12-17 The Salk Institute For Biological Studies Evectins and their use
US7049290B2 (en) 2000-07-28 2006-05-23 Universität Zürich Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
AU2001284942A1 (en) 2000-08-16 2002-02-25 Georgetown University Medical Center Small molecule inhibitors targeted at bcl-2
CA2432111A1 (en) 2000-12-19 2002-08-22 The Johns Hopkins University Jfy1 protein induces rapid apoptosis
CA2471719A1 (en) 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
US7524630B2 (en) 2002-04-22 2009-04-28 University Of Florida Research Foundation, Inc. Functionalized nanoparticles and methods of use
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20040171809A1 (en) 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
KR100699614B1 (ko) 2002-11-08 2007-03-23 에프. 호프만-라 로슈 아게 퍼옥시좀 증식자 활성화된 수용체 작용제로서의 치환된4-알콕시옥사졸 유도체
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
JP2007537989A (ja) 2003-10-16 2007-12-27 アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 安定化ペプチド
EP2332968B1 (en) * 2003-11-05 2016-05-04 Dana-Farber Cancer Institute, Inc. Alpha-helical peptides suitable for activating or inhibiting cell death
GB0404731D0 (en) 2004-03-03 2004-04-07 Indp Administrative Inst Nims Method and products for the selective degradation of proteins
EP1737884B1 (en) 2004-03-19 2016-10-19 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US7202332B2 (en) * 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
US7501397B2 (en) 2004-06-04 2009-03-10 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity
WO2006103666A2 (en) 2005-03-28 2006-10-05 Yeda Research And Development Co. Ltd. Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
US7917612B2 (en) * 2005-05-25 2011-03-29 Oracle International Corporation Techniques for analyzing commands during streaming media to confirm delivery
US7538190B2 (en) * 2006-02-17 2009-05-26 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of two or more dicarba bridges in organic compounds
US7745573B2 (en) * 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
CA2686827C (en) 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP3301108A1 (en) * 2007-02-23 2018-04-04 Aileron Therapeutics, Inc. Triazole macrocycle systems
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
US20090326192A1 (en) 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
ES2666458T3 (es) * 2008-09-22 2018-05-04 Aileron Therapeutics, Inc. Macrociclos peptidomiméticos
US9458202B2 (en) 2008-11-24 2016-10-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
CA2746256C (en) 2008-12-09 2020-03-24 Loren D. Walensky Methods and compositions for specific modulation of mcl-1
CA2777700A1 (en) * 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
JP2014520120A (ja) 2011-06-17 2014-08-21 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化した変異型ｍａｍｌペプチドおよびその使用
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function

Also Published As

Publication number Publication date
US8198405B2 (en) 2012-06-12
CA2830063C (en) 2017-10-31
CN1906209A (zh) 2007-01-31
IL175152A0 (en) 2006-09-05
EP1997828A3 (en) 2008-12-10
EP1680443A2 (en) 2006-07-19
EP2332967A1 (en) 2011-06-15
US20120082636A1 (en) 2012-04-05
US20170008930A1 (en) 2017-01-12
EP2332967B1 (en) 2016-04-20
EP1680443A4 (en) 2008-09-24
JP2015163608A (ja) 2015-09-10
ES2586387T3 (es) 2016-10-14
US9464115B2 (en) 2016-10-11
PT1680443E (pt) 2013-12-11
US20090176964A1 (en) 2009-07-09
JP2012116836A (ja) 2012-06-21
US7723469B2 (en) 2010-05-25
DK1680443T5 (en) 2015-02-02
CY1114944T1 (el) 2016-12-14
ES2437567T3 (es) 2014-01-13
JP2019189622A (ja) 2019-10-31
CN103467588B (zh) 2016-12-28
IL175152A (en) 2014-11-30
EP2332968A1 (en) 2011-06-15
CN107090025A (zh) 2017-08-25
CA2544223C (en) 2017-03-07
US20050250680A1 (en) 2005-11-10
IL235348B (en) 2018-02-28
HK1089191A1 (en) 2006-11-24
US8796418B2 (en) 2014-08-05
DK1680443T3 (da) 2013-12-16
ZA200603565B (en) 2007-12-27
AU2004287884C1 (en) 2012-11-29
JP2008501623A (ja) 2008-01-24
JP5122142B2 (ja) 2013-01-16
AU2004287884A1 (en) 2005-05-19
WO2005044839A2 (en) 2005-05-19
CN103467588A (zh) 2013-12-25
PL1680443T3 (pl) 2014-02-28
WO2005044839A3 (en) 2005-07-28
PT2332968T (pt) 2016-08-17
BRPI0416258A (pt) 2007-01-09
CA2830063A1 (en) 2005-05-19
DK2332968T3 (en) 2016-08-22
US20090149630A1 (en) 2009-06-11
IL247907B (en) 2019-02-28
EP1680443B1 (en) 2013-09-04
EP1997828B1 (en) 2017-10-04
EP2332968B1 (en) 2016-05-04
EP1997828A2 (en) 2008-12-03
US20140296160A1 (en) 2014-10-02
SI1680443T1 (sl) 2014-01-31
JP2017197522A (ja) 2017-11-02
US9273099B2 (en) 2016-03-01
CA2544223A1 (en) 2005-05-19
EP1680443B9 (en) 2014-09-03
AU2004287884B2 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
PT2332968T (pt) Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular
HK1083443A1 (en) Thiazolidin-4-ones for inhibiting hyak3 proteins
EP1626981A4 (en) PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
GB2402334B (en) Coenzyme-Q10 containing composition with improved bioavailability
IL166668A0 (en) Patches containing turobuterol
EP1500402A4 (en) INHIBITOR OF CELL DEATH
EP1591523A4 (en) OVEREXPRESSION VECTOR FOR PET CELL
EP1596813A4 (en) POLYPEPTIDES EXPRESSED BY LUNGS
GB2405706B (en) Multi-variable operations
EP1717244A4 (en) POLYPEPTIDE SPECIFICALLY INHIBITING AKT ACTIVITY
AU2003256401A8 (en) Backterial effector proteins which inhibit programmed cell death
AU2003303051A8 (en) Cell death inhibitor
EP1596815A4 (en) COMPOSITION AND METHOD FOR INHIBITING THE SURVIVAL OF CELLS
EP1596815A3 (en) Composition and methods for inhibiting cell survival
GB2405853B (en) Material handling
GB0322317D0 (en) Expansin polypeptide
GB0300322D0 (en) Gas container
AU2003230992A8 (en) Peptides and methods for cell death regulation
AU2003217656A8 (en) Storage rack for human transporter
TW559445U (en) Waterproof structure for sensor case
GB0315930D0 (en) Polypeptide
GB0327685D0 (en) Polypeptide
GB0313754D0 (en) Polypeptide
GB0313752D0 (en) Polypeptide
GB0308088D0 (en) Polypeptide